AGN:CSE; AGNPF:OTCQB; AGN0:XFRA

Algernon Pharmaceuticals Inc.

Algernon is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for its lead drug NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.
AGN:CSE AGNPF:OTCQB AGN0:XFRA

Expert Comments:

read more >
AlphaNorth Asset Management was recently recognized as the Number One equity hedge fund in Canada at the 2021 Alternative IQ Canadian Hedge Fund Awards due to its 5-year average investment return of 40.35%. Streetwise Reports sat down with the firm's co-Founder Steven Palmer to discuss some of the firm's recent investments and emerging opportunities for 2022.
read more >
read more >
Drug re-purposing co. Algernon Pharmaceuticals Inc. is actively reinventing itself. The firm's leading therapeutic candidate NP-120 (Ifenprodil) is currently being evaluated in a Phase 2 trial for IPF and chronic cough, and the company is now moving forward with a revolutionary new use for DMT to treat ischemic stroke.
read more >

Clive Maund, CliveMaund.com

(2/2/22)
"We can see entry and exit points on the latest three-month chart of Algernon Pharmaceuticals Inc. stock and how it has reacted back in a satisfactory manner to another good buy spot, with the technical setup now very positive. The time has thus arrived to buy back the position we sold at a much higher price; it is rated a Strong buy again here, especially as the broad stock market is on the up again."

read more >
read more >
headshot of André Uddin

André Uddin, Research Capital Corporation

(1/28/22)
"For Algernon Pharmaceuticals Inc., the results of the ongoing Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough (Q2/22) represent an important near-term catalyst investors should watch. . .we believe the company is back on track and focused on developing its pipeline. We consider Algernon's current valuation favorable from a risk-reward standpoint."

read more >

Clive Maund, CliveMaund.com

(1/19/22)
"As we can see on its latest six-month chart, Algernon Pharmaceuticals Inc.'s stock has soared. . .we have certainly done well with this, having about doubled our money in a month."

headshot of Bob Moriarty

Bob Moriarty, 321 Gold

(1/18/22)
"Algernon Pharmaceuticals Inc. has a lot of potential, and I placed my bet with shares bought in the open market. . .the company has a lot of good things in the works, and there should be a constant flow of news. It's the kind of company that could be a $500M market cap in a takeout after success in any one of several drug trials."

read more >

Clive Maund, CliveMaund.com

(1/12/22)
"Long-term charts show Algernon Pharmaceuticals Inc. stock to be very cheap. As it now has only 1.6M shares in issue after a 1 for 100 rollback, it has big upside potential. . .the company remains a Buy here and especially on any minor dips, if any."

read more >

Clive Maund, CliveMaund.com

(12/22/21)
"Algernon Pharmaceuticals Inc. stock has now arrived at what looks like a long-term cyclical low at the support at its late 2019 lows, which is a good point for it to turn, and that's what it looks like it is in the process of doing. . .the fundamentals of the company are believed to be positive. The conclusion is that Algernon is rated an attractive Speculative Buy here."

More Expert Comments

Experts Following This Company

Clive Maund – CliveMaund.com
headshot of Bob Moriarty
Bob Moriarty, Author – 321 Gold
headshot of Penny Queen
Penny Queen, Mother, Investor and Social Media Leader
headshot of André Uddin
André Uddin – Research Capital Corporation

Company News 

5/5/2022 – Algernon Pharmaceuticals Announces Last Patient Treated in Phase 2 Study of IPF and Chronic Cough

4/26/2022 – Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study

2/23/2022 – Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program

1/19/2022 – Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights
 
Advancing new drug treatments for billion dollar global disease markets.
 
Conducting multiple phase II clinical trials
 
Experienced management team & globally recognized medical advisory board
catalyst Calendar
Q2
2021
U,S, FDA End-of-Phase 2 COVID-19 Study Meeting, Q2, 2021
Q4
2021
Phase 2 trial for IPF and chronic cough data expected Q4, 2021.
Q4
2021
Phase 1 Study planned for DMT, Q4 2021